Apr 8, 2026 07:30AM Innoviva (INVA) Reiterated at Overweight by Cantor Fitzgerald After Webinars on New Segment

Feb 26, 2026 10:03AM Inova Technology, Inc. (INVA) PT Raised to $32 at Cantor Fitzgerald on Improved Outlook

Feb 26, 2026 02:42AM Innoviva (INVA) Reports Q4 EPS of $1.94

Feb 17, 2026 06:59AM BTIG Starts Innoviva (INVA) at Buy

Dec 16, 2025 06:53AM Inova Technology, Inc. (INVA) PT Raised to $46 at H.C. Wainwright

Nov 5, 2025 05:46PM Innoviva (INVA) Tops Q3 EPS by 60c

Sep 30, 2025 05:07AM Goldman Sachs Starts Inova Technology, Inc. (INVA) at Sell, PT $17

Aug 11, 2025 06:49AM Oppenheimer Starts Inova Technology, Inc. (INVA) at Outperform

Aug 6, 2025 05:29PM Innoviva (INVA) Tops Q2 EPS by 31c

Jul 11, 2025 06:44AM Cantor Fitzgerald Starts Inova Technology, Inc. (INVA) at Overweight

Jun 12, 2025 07:00AM Innoviva (INVA): FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Jun 10, 2025 06:01AM Innoviva (INVA) Receives FDA New Drug Application Acceptance for Zoliflodacin

May 7, 2025 04:51PM Innoviva (INVA) Misses Q1 EPS by 107c

Mar 12, 2025 05:09PM Armata Pharma (ARMP) announces secure credit agreement of $10 million with Innoviva

Mar 7, 2025 07:11AM Scotiabank Starts Inova Technology, Inc. (INVA) at Sector Outperform

Feb 26, 2025 04:05PM Innoviva (INVA) Misses Q4 EPS by 6c

Dec 16, 2024 07:01AM Innoviva (INVA) Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera

Nov 6, 2024 04:47PM Innoviva (INVA) Misses Q3 EPS by 25c

Jul 31, 2024 05:50PM Innoviva (INVA) Misses Q2 EPS by 79c

Jun 18, 2024 06:04AM Cantor Fitzgerald Reiterates Overweight Rating on Inova Technology, Inc. (INVA)